NL-OMON27928招募中不适用
Phase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non-small cell lung cancer.
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 126
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Inclusion criteria for Oligometastatic disease (max 5 metastases) or Poly-metastatic disease (6-10 metastases) are different.
- •- For patients with Oligometastatic disease:
- •Histological confirmed limited metastatic adult NSCLC patients, regardless of the PD-L1 status.
- •Maximum of 5 metastatic lesions, a maximum of two brain lesion with a total cumulative diameter of 5 cm is allowed.
- •Previous treatment:
- •oPrior cancer treatments are allowed but must be discontinued for at least 4 weeks before randomisation. In case of maintenance chemotherapy, this therapy will only be started after the end of the L19-IL2 treatment or only in case of Anti-PD(L)1 treatment, during L19-IL2 therapy.
- •Age of 18 years or older.
- •WHO performance status 0-1;
- •Adequate bone marrow function (Absolute Neutrophil Count (ANC) of = 1.0 x 109 /L, platelet count = 100 x 109/L, Hb = 6.0 mmol/L (or 9.67 g/dL) (it is allowed to give a blood transfusion if Hb is initially too low))
- •Adequate hepatic function (total bilirubin = 1.5 x upper limit of normal (ULN) for the institution; ALT, AST, and alkaline phosphatase = 2.5 x ULN for the institution or = 5 in case of liver metastasis));
- •Adequate renal function (creatinine clearance of at least 40 ml/min);
- •The patient is capable of complying with study procedures;
- •Life expectancy of at least 12 weeks;
- •Negative serum pregnancy test for females of childbearing potential.
- •Ability to comply with contraception requirements:
- •Signed and dated written informed consent;
- •- For patients with Poly-metastatic disease (6 to 10 metastases):
- •Histological confirmed limited metastatic adult NSCLC patients, regardless of the PD-L1 status.
- •Minimum of 6 and maximum of 10 metastatic lesions, a maximum of two brain lesion with a total cumulative diameter of 5 cm is allowed.
- •Previous treatment:
- •oThe time between the last administration of chemo and/or immunotherapy (given as first or second line standard of care treatment) and the randomisation must be at least 4 weeks. In case of maintenance chemotherapy, this therapy will only be started after the end of the L19-IL2 treatment or only in case of Anti-PD(L)1 treatment, during L19-IL2 therapy
- •Age of 18 years or older.
- •WHO performance status 0-1;
- •Adequate bone marrow function (Absolute Neutrophil Count (ANC) of = 1.0 x 109 /L, platelet count = 100 x 109/L, Hb = 6.0 mmol/L (or 9.67 g/dL) (it is allowed to give a blood transfusion if Hb is initially too low))
- •Adequate hepatic function (total bilirubin = 1.5 x upper limit of normal (ULN) for the institution; ALT, AST, and alkaline phosphatase = 2.5 x ULN for the institution or = 5 in case of liver metastasis));
- •Adequate renal function (creatinine clearance of at least 40 ml/min);
- •The patient is capable of complying with study procedures;
- •Life expectancy of at least 12 weeks;
- •Negative serum pregnancy test for females of childbearing potential.
- •Ability to comply with contraception requirements:
- •Signed and dated written informed consent;
排除标准
- •More than 10 metastatic lesions.
- •More than 2 brain metastatic lesions.
- •2 brain metastases with a cumulative diameter larger than 5 cm.
- •Patients with non-infectious pneumonitis, uncontrolled thyroid disease, pleuritis, pericarditis and peritonitis carcinomatosis
- •Patients who received live vaccines 30 days or fewer prior to enrolment.
- •Patients who are already actively participating in another study.
- •Patients who need simultaneous radiation on the primary tumour and metastatic lesion(s). For these patients it might be an option to treat the primary tumour first although this is not mandatory for this study. There must be minimal 4 weeks between last treatment and randomisation.
- •Whole brain radiotherapy (WBRT) is not allowed, although it is accepted when given at least 4 weeks prior to randomisation or after the treatment period. Patients with stable brain metastases are not excluded.
- •Previous radiotherapy to an area that would be re-treated by (SAB)R, resulting in overlap of the high dose areas.
- •Maintenance therapy with Anti-PD(L)1 treatment combined with chemotherapy is not allowed during treatment ((SAB)R and L19-IL2 cycles).
- •Other active malignancy or malignancy within the last 2 years (except localised skin basal/squamous cell carcinoma, non-muscle invasive carcinoma of the bladder or in situ carcinoma from any site).
- •Concomitantly administered glucocorticoids may decrease the activity of IL2 and therefore should be avoided. However, patients who develop life-threatening signs or symptoms may be treated with dexamethasone until toxicity resolves or reduces to an acceptable level (generally grade 1 and 2, however must be based at the research physician’s discretion).
- •History of allergy to intravenously administered proteins/peptides/antibodies/ radiographic contrast media.
- •HIV positive; active HIV infection, or active hepatitis B or C (assessed in local lab).
- •Systemic treatment with either corticosteroid (>10 mg daily prednisone equivalents) or Interferon alpha or immunosuppressive medications within 14 days prior to randomisation. Topical or inhalation steroids are allowed. If a patient needs to take unexpectedly immunosuppressive medication during the trial, it will be allowed but decreasing the dose as soon as possible is strongly advised.
- •Prior history of organ transplant, including autologous stem cell transplant.
- •Acute or sub-acute coronary syndromes within the last year, acute inflammatory heart disease, heart insufficiency NYHA > 2, or irreversible cardiac arrhythmias.
- •A known impaired cardiac function defined as left ventricular ejection fraction (LVEF) < 50 % (or below the study site’s lower limit of normal) as measured by MUGA or ECHO.
- •Uncontrolled hypertensive disease; (systolic blood pressure (SBP) =160 or diastolic blood pressure (DBP) =100 mm Hg during two measurements).
- •History or evidence of active autoimmune disease.
- •Severe diabetic retinopathy (neoangiogenesis targeted by L19 outside the tumour).
- •Major trauma, including oncologic surgery, but excluding smaller procedures like the placement of porth-à-cath or surgical biopsy, within 4 weeks prior to randomisation (neoangiogenesis targeted by L19 outside a tumour).
- •Any underlying mental, medical or psychiatric condition which in the opinion of the investigator will make administration of study drug hazardous or hinder the interpretation of study results. Unstable or serious concurrent uncontrolled medical conditions.
研究者
相似试验
进行中（未招募）
1 期
The trial will consist of one cohort of adult patients with Stage IV metastatic NSCLCEUCTR2018-002583-11-NLMaastricht University Medical Centre126
进行中（未招募）
1 期
The trial will consist of one cohort of adult patients with Stage IV metastatic NSCLCPatients with progressive lung cancer with a maximum of 10 metastatic lesions will receive Standard Of Care radiotherapy combined with immunotherapyMedDRA version: 20.0Level: LLTClassification code 10025044Term: Lung cancerSystem Organ Class: 100000004864EUCTR2018-002583-11-ITMaastricht University126
进行中（未招募）
1 期
The trial will consist of one cohort of adult patients with Stage IV metastatic NSCLCThe trial will consist of one cohort of adult patients with Stage IV metastatic NSCLCMedDRA version: 20.0 Level: LLT Classification code 10025044 Term: Lung cancer System Organ Class: 100000004864EUCTR2018-002583-11-FRMaastricht University Medical Centre126
招募中
2 期
Phase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non-small cell lung cancerong kankerprogressive Lung cancerNL-OMON56015niversiteit Maastricht56
进行中（未招募）
1 期
The trial will consist of one cohort of adult patients with Stage IV metastatic NSCLCThe trial will consist of one cohort of adult patients with Stage IV metastatic NSCLCMedDRA version: 20.0Level: LLTClassification code 10025044Term: Lung cancerSystem Organ Class: 100000004864EUCTR2018-002583-11-GBMaastricht University Medical Centre126